Anticancer Drug Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication (Breast Cancer, Blood Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer, Others), By Drug (Cytotoxic, Hormonal Therapy, Targeted Therapy, Others), By Route of Administration (Oral, Parenteral, Others), By End User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region and Competition, 2020-2030F

Market Overview

The Global Anticancer Drug Market, valued at USD 179.93 Billion in 2024, is projected to experience a CAGR of 5.25% to reach USD 244.59 Billion by 2030. Anticancer drugs represent pharmaceutical agents specifically formulated to inhibit or destroy malignant cells, serving as the cornerstone for various cancer treatment strategies. The market's expansion is primarily driven by the escalating global incidence of cancer, an expanding aging population predisposed to oncological diseases, and continuous advancements in medical research that foster novel therapeutic breakthroughs. According to the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), the top 50 pharmaceutical companies collectively spent an estimated USD 167 billion on research and development in 2022.

Further market momentum is generated by increasing healthcare expenditures and improvements in diagnostic capabilities, facilitating earlier and more accurate disease detection. Nevertheless, a significant challenge impeding market growth is the considerable cost associated with the development and provision of advanced therapies, which can restrict patient access and affordability, particularly within emerging economies.

Key Market Drivers

The increasing global cancer incidence substantially propels the anticancer drug market. A growing patient population naturally leads to a higher demand for diagnostic tools and subsequent therapeutic interventions, from chemotherapy to advanced targeted therapies. This demographic shift intensifies the need for a continuous supply of effective pharmaceuticals, driving companies to expand their portfolios. According to the International Agency for Research on Cancer, in 2022, there were an estimated 20 million new cancer cases worldwide, indicating a vast and expanding patient pool requiring treatment. The persistent rise in various cancer types underscores the demand for innovative drug solutions.

Concurrently, advancements in oncology research and development are a critical driver, introducing novel therapeutic options and improving patient outcomes, thereby sustaining market growth. Continuous investment in biotechnology and genomics facilitates the discovery of new drug targets and the creation of highly specialized treatments such as antibody-drug conjugates. This pursuit of innovation is evidenced by substantial collaborations within the industry; according to GeneOnline, in September 2024, "Biotech Industry Trends in 2024: A Look at the Billions in Oncology Deals", a landmark $22 billion agreement between Daiichi Sankyo and Merck & Co. occurred in October 2023, focusing on three antibody-drug conjugates for solid tumors. Such financial commitments accelerate the pipeline of new drugs. Furthermore, the robust performance of leading pharmaceutical firms highlights the market's overall strength; according to Fierce Pharma, in February 2024, Roche's oncology business remained its largest segment, with its PD-L1 inhibitor Tecentriq generating CHF 3.77 billion in sales in 2023. These factors collectively underscore a dynamic and expanding global anticancer drug market.

Download Free Sample Report

Key Market Challenges

A significant challenge impeding the growth of the global anticancer drug market is the considerable cost associated with the development and provision of advanced therapies. These high costs directly restrict patient access and affordability, particularly within emerging economies. This limitation reduces the eligible patient population for novel treatments, thereby hampering market penetration and overall sales volumes globally.

The financial burden on healthcare systems and individual patients results in delayed or denied access to innovative drugs. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), in 2023, the average time to reimbursement for innovative treatments across EU and European Economic Area countries reached 531 days, indicating substantial delays in patient access due to pricing and reimbursement complexities. Furthermore, a 2023 report from the Pharmaceutical Research and Manufacturers of America (PhRMA) indicated that patients in OECD countries, on average, had access to only 29% of new medicines through a government health plan, compared to 85% in the United States, showcasing a significant disparity in market reach driven by economic factors and healthcare policies.

Key Market Trends

The integration of artificial intelligence (AI) in oncology is profoundly reshaping drug discovery and development processes. AI algorithms can analyze vast datasets, identify novel drug targets, and predict compound efficacy with increased speed and accuracy compared to traditional methods. This technological advancement significantly reduces the time and cost associated with bringing new anticancer drugs to market, fostering a more efficient and productive pipeline. According to Silicon Valley Bank, biotech AI attracted $5.6 billion in 2024, constituting nearly 30% of healthcare startup funding, reflecting a substantial increase driven by significant investment deals. This influx of capital underscores the industry's confidence in AI's transformative potential. For example, Insilico Medicine announced in June 2023 that its small molecule inhibitor drug candidate, INS018_055, an entirely AI-discovered and AI-designed drug, entered a phase 2 clinical trial for idiopathic pulmonary fibrosis, demonstrating the tangible progress of AI in therapeutic advancement.

The adoption of advanced cell and gene therapies represents a paradigm shift in cancer treatment, moving beyond conventional pharmaceuticals to leverage living cells and genetic material for therapeutic effect. These therapies, including CAR T-cells and gene-edited solutions, offer highly personalized approaches capable of targeting cancer cells with remarkable specificity and persistence. Their increasing clinical use expands treatment options for patients with previously intractable cancers, stimulating significant investment and development within this specialized segment. The American Society of Gene & Cell Therapy reported that 64% of the 80 gene therapy trials initiated in the second quarter of 2025 were specifically for oncology indications, marking the highest proportion in the past year. This strong focus on cancer underscores the critical role these innovative modalities play in the evolving anticancer drug market. GT Biopharma, Inc. announced in October 2025 that patients in Cohort 3 of its Phase 1 trial for GTB-3650, targeting relapsed or refractory CD33-expressing blood cancers, successfully initiated treatment with no dose-limiting toxicities, highlighting ongoing progress in cell and gene therapy clinical development for oncological diseases.

Segmental Insights

The breast cancer segment is a primary driver of expansion within the global anticancer drug market, experiencing rapid growth attributed to several factors. The rising incidence and prevalence of breast cancer worldwide continue to necessitate effective therapeutic solutions. This growth is significantly fueled by ongoing advancements in novel treatment modalities, including targeted therapies and immunotherapies, which offer improved patient outcomes and expanded treatment options. Furthermore, enhanced diagnostic capabilities and increased public awareness, coupled with a supportive regulatory landscape from bodies such as the U. S. Food and Drug Administration, facilitate faster drug development and adoption.

Regional Insights

North America holds a dominant position in the global anticancer drug market due to several key factors. The region benefits from a highly developed healthcare infrastructure, encompassing advanced hospitals and specialized cancer research centers, which facilitates the widespread adoption of new therapies. Substantial investments in innovative anticancer therapies, propelled by robust research and development efforts from major pharmaceutical companies, consistently introduce novel treatments to the market. The increasing prevalence of cancer within an aging and expanding population further generates sustained demand for these essential drugs. Additionally, supportive government regulations and rigorous drug approval processes, exemplified by the U. S. Food and Drug Administration's Office of Oncologic Diseases, ensure the availability of safe and effective treatments.

Recent Developments

• In June 2025, Bristol Myers Squibb entered an $11 billion strategic collaboration agreement with BioNTech. The partnership involves the co-development and co-commercialization of BioNTech's investigational bispecific antibody, BNT327, targeting various solid tumor types. BioNTech received an upfront payment of $1.5 billion, with additional non-contingent anniversary payments through 2028 and potential milestone payments up to $7.6 billion. This collaboration represents a significant investment in advancing novel immuno-oncology therapies within the global anticancer drug market, aiming to accelerate the development of this bispecific antibody in multiple indications.

• In January 2025, Marengo Therapeutics Inc. announced that its first-in-class selective dual T-cell agonist, invikafusp alfa (STAR0602), received Fast Track designation from the U.S. Food and Drug Administration. This designation was granted for the treatment of patients with advanced colorectal cancer characterized by a high tumor mutational burden. The Fast Track status is expected to expedite the development and review process for invikafusp alfa, recognizing its potential to address an unmet medical need in colorectal cancer where current treatment options are limited within the global anticancer drug market.

• In October 2024, Merck announced that its anti-PD-1 therapy, KEYTRUDA (pembrolizumab), received two new indications from the European Commission for gynecologic cancers. The approvals included KEYTRUDA in combination with carboplatin and paclitaxel for the first-line treatment of primary advanced or recurrent endometrial carcinoma. Additionally, KEYTRUDA in combination with chemoradiotherapy was approved for the treatment of FIGO 2014 Stage III-IVA locally advanced cervical cancer. These expanded indications for KEYTRUDA underscore its broadening utility in diverse patient populations within the global anticancer drug market.

• In April 2024, Roche's cancer drug, Alecensa (alectinib), received expanded approval from the U.S. Food and Drug Administration. This approval allows for its use as an adjuvant treatment following tumor resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer. This marks Alecensa as the first and only ALK inhibitor approved for individuals with ALK-positive early-stage NSCLC who have undergone surgery. The decision was based on Phase III study results demonstrating a 76 percent reduction in the risk of disease recurrence or death compared to chemotherapy, representing a significant advancement in the global anticancer drug market.

Key Market Players

• F. Hoffmann-La Roche Ltd.
• Genentech, Inc.
• Novartis AG
• Pfizer Inc.
• Bristol-Myers Squibb Company
• GlaxoSmithKline plc.
• Eli Lilly and Company (India) Pvt. Ltd.
• AstraZeneca plc
• Sanofi S.A.
• Bayer AG

Report Scope:

In this report, the Global Anticancer Drug Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Anticancer Drug Market, By Indication:

o   Breast Cancer

o   Blood Cancer

o   Prostate Cancer

o   Gastrointestinal Cancer

o   Gynaecologic Cancer

o   Lung Cancer

o   Others

• Anticancer Drug Market, By Drug:

o   Cytotoxics

o   Hormonal Therapy

o   Targeted Therapy

o   Others

• Anticancer Drug Market, By Route of Administration:

o   Oral

o   Parenteral

o   Others

• Anticancer Drug Market, By End User:

o   Hospitals & Clinics

o   Ambulatory Care Centers

o   Others

• Anticancer Drug Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Anticancer Drug Market.

Available Customizations:

Global Anticancer Drug Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Anticancer Drug Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]